Literature DB >> 7799336

Phenotypic characteristics of bone marrow cells in patients with rheumatoid arthritis.

T Tomita1, N Kashiwagi, Y Shimaoka, T Ikawa, M Tanabe, S Nakagawa, S Kawamura, K Denno, H Owaki, T Ochi.   

Abstract

OBJECTIVE: Our previous study showed the presence of abnormal myeloid lineage cells in the epiphyseal bone marrow adjacent to joints affected with severe rheumatoid arthritis (RA). Now, we investigated whether there were any changes of other marrow cell populations related to RA, and whether there were any pathologically characteristic changes in the iliac bone marrow, which is one of the major systemic hematopoietic organs.
METHODS: 2-Color flow cytometry was carried out to analyze the phenotypes of mononuclear cells (MNC) fractions in bone marrow aspirates and venous blood from 56 patients with RA and 7 non-RA controls.
RESULTS: The absolute number of MNC in the iliac bone marrow was increased by 3-fold in the RA patients compared with the non-RA controls. In contrast, no significant increase of MNC was observed in the tibial epiphyseal bone marrow or peripheral blood. The ratio of each MNC fraction in the iliac bone marrow did not differ significantly between the RA patients and the non-RA controls. In lymphocyte subsets, the percentage of HLA-DR+CD8+ cells to all CD8 cells in the iliac bone marrow increased significantly in the RA patients compared with the non-RA controls. Abnormal myeloid cells (MX-GA+MY4+ cells), specific to severe RA, were found to be more concentrated in the iliac bone marrow than in the tibial epiphyseal bone marrow.
CONCLUSION: Characteristic pathologic changes of the iliac bone marrow suggest an important role of systemic bone marrow in the progression of RA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7799336

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  The CD8+ HLA-DR+ T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls.

Authors:  Hiromi Imamichi; Richard A Lempicki; Joseph W Adelsberger; Rebecca B Hasley; Alice Rosenberg; Gregg Roby; Catherine A Rehm; Amy Nelson; Sonya Krishnan; Mark Pavlick; Christian J Woods; Michael W Baseler; H Clifford Lane
Journal:  Eur J Immunol       Date:  2012-08-06       Impact factor: 5.532

2.  Increase of CD57+ T cells in knee joints and adjacent bone marrow of rheumatoid arthritis (RA) patients: implication for an anti-inflammatory role.

Authors:  K Arai; S Yamamura; S Seki; T Hanyu; H E Takahashi; T Abo
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

3.  Monocytes/macrophages express chemokine receptor CCR9 in rheumatoid arthritis and CCL25 stimulates their differentiation.

Authors:  Caroline Schmutz; Alison Cartwright; Helen Williams; Oliver Haworth; John H H Williams; Andrew Filer; Mike Salmon; Christopher D Buckley; Jim Middleton
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

4.  The non-leukemic T cell large granular lymphocytic leukemia variant with marked splenomegaly and neutropenia in the setting of rheumatoid arthritis - Felty syndrome and hepatosplenic T cell lymphoma mask.

Authors:  Vadim Gorodetskiy; Natalya Probatova; Yulia Sidorova; Natalia Kupryshina; Tatiana Obukhova; Vladimir Vasilyev; Natalya Ryzhikova; Andrey Sudarikov
Journal:  Am J Blood Res       Date:  2021-06-15

Review 5.  Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective.

Authors:  Serena Bugatti; Antonio Manzo; Roberto Caporali; Carlomaurizio Montecucco
Journal:  Arthritis Res Ther       Date:  2012-12-27       Impact factor: 5.156

Review 6.  Fcγ and Complement Receptors and Complement Proteins in Neutrophil Activation in Rheumatoid Arthritis: Contribution to Pathogenesis and Progression and Modulation by Natural Products.

Authors:  Adriana Balbina Paoliello-Paschoalato; Larissa Fávaro Marchi; Micássio Fernandes de Andrade; Luciana Mariko Kabeya; Eduardo Antônio Donadi; Yara Maria Lucisano-Valim
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-05       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.